Dost R, Rostock A, Rundfeldt C
elbion AG, Meissner Strasse 191, 01445 Radebeul, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):382-90. doi: 10.1007/s00210-004-0881-1. Epub 2004 Mar 9.
Retigabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester) has a broad anticonvulsant spectrum and is currently in clinical development for epilepsy. The compound has an opening effect on neuronal KCNQ channels. At higher concentrations an augmentation of gamma-aminobutyric acid (GABA) induced currents as well as a weak blocking effect on sodium and calcium currents were observed. The goal of this study was to characterise the activity of retigabine in models of acute and neuropathic pain and to investigate if the potassium channel opening effect of retigabine contributes to its activity. Retigabine was tested in mice and rats in the tail flick model of acute pain and in the nerve ligation model with tight ligation of the 5th spinal nerve (L5) using both thermal and tactile stimulation. While retigabine like gabapentin had almost no analgesic effect in mice it showed some analgesic effects in rats in the tail flick model. These effects could not be antagonised with linopirdine, a selective KCNQ potassium channel blocker, indicating a different mode of action for this activity. In L5-ligated rats retigabine significantly and dose-dependently elevated the pain threshold and prolonged the withdrawal latency after tactile and thermal stimulation, respectively. In the L5 ligation model with thermal stimulation retigabine 10 mg/kg p.o. was as effective as 100 mg/kg gabapentin or 10 mg/kg tramadol. The L5 model with tactile stimulation was used to test the role of the KCNQ potassium channel opening effect of retigabine. If retigabine 10 mg/kg p.o. was administered alone it was as effective as tramadol 10 mg/kg p.o. in elevating the pain threshold. Linopirdine (1 and 3 mg/kg i.p.) had nearly no influence on neuropathic pain response. If we administered both retigabine and linopirdine the effect of retigabine was abolished or diminished depending on the dose of linopirdine used.In summary, retigabine is effective in predictive models for neuropathic pain. The activity is comparable to tramadol and is present at lower doses compared with gabapentin. Since the anti-allodynic effect can be inhibited by linopirdine we can conclude that the potassium channel opening properties of retigabine are critically involved in its ability to reduce neuropathic pain response.
瑞替加滨(N-(2-氨基-4-(4-氟苄基氨基)-苯基)氨基甲酸乙酯)具有广泛的抗惊厥谱,目前正处于癫痫的临床开发阶段。该化合物对神经元KCNQ通道具有开放作用。在较高浓度下,观察到γ-氨基丁酸(GABA)诱导电流增强以及对钠电流和钙电流有微弱的阻断作用。本研究的目的是在急性和神经性疼痛模型中表征瑞替加滨的活性,并研究瑞替加滨的钾通道开放作用是否有助于其活性。在小鼠和大鼠中,使用热刺激和触觉刺激,在急性疼痛的甩尾模型以及第5腰神经(L5)紧密结扎的神经结扎模型中对瑞替加滨进行了测试。虽然瑞替加滨与加巴喷丁一样在小鼠中几乎没有镇痛作用,但在大鼠甩尾模型中显示出一些镇痛作用。这些作用不能被选择性KCNQ钾通道阻滞剂利诺吡啶拮抗,表明该活性的作用方式不同。在L5结扎的大鼠中,瑞替加滨分别显著且剂量依赖性地提高了疼痛阈值,并延长了触觉和热刺激后的撤针潜伏期。在热刺激的L5结扎模型中,口服10 mg/kg的瑞替加滨与100 mg/kg的加巴喷丁或10 mg/kg的曲马多效果相同。使用触觉刺激的L5模型来测试瑞替加滨的KCNQ钾通道开放作用的作用。如果单独给予口服10 mg/kg的瑞替加滨,其提高疼痛阈值的效果与口服10 mg/kg的曲马多相同。利诺吡啶(1和3 mg/kg腹腔注射)对神经性疼痛反应几乎没有影响。如果同时给予瑞替加滨和利诺吡啶,瑞替加滨的作用会根据所用利诺吡啶的剂量而被消除或减弱。总之,瑞替加滨在神经性疼痛的预测模型中有效。其活性与曲马多相当,与加巴喷丁相比,在较低剂量时就有活性。由于抗痛觉过敏作用可被利诺吡啶抑制,我们可以得出结论,瑞替加滨的钾通道开放特性与其减轻神经性疼痛反应的能力密切相关。